Equities research analysts predict that Orchard Therapeutics PLC – (NASDAQ:ORTX) will report sales of $560,000.00 for the current quarter, Zacks reports. Two analysts have provided estimates for Orchard Therapeutics’ earnings, with the highest sales estimate coming in at $600,000.00 and the lowest estimate coming in at $510,000.00. The firm is expected to announce its next quarterly earnings report on Monday, January 1st.
On average, analysts expect that Orchard Therapeutics will report full year sales of $2.24 million for the current fiscal year, with estimates ranging from $2.08 million to $2.39 million. For the next year, analysts expect that the company will report sales of $3.64 million, with estimates ranging from $2.14 million to $5.14 million. Zacks’ sales calculations are an average based on a survey of research firms that follow Orchard Therapeutics.
Several equities research analysts have recently weighed in on the stock. Zacks Investment Research lowered shares of Orchard Therapeutics from a “buy” rating to a “hold” rating in a report on Tuesday, April 2nd. Wedbush reaffirmed an “outperform” rating and issued a $25.00 target price on shares of Orchard Therapeutics in a report on Friday, March 22nd. Two analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. The company has a consensus rating of “Buy” and an average price target of $23.40.
Shares of ORTX traded down $0.11 during trading hours on Friday, hitting $18.51. The stock had a trading volume of 2,813 shares, compared to its average volume of 100,987. Orchard Therapeutics has a 52 week low of $8.65 and a 52 week high of $21.64. The firm has a market cap of $1.61 billion and a price-to-earnings ratio of -1.82.
Orchard Therapeutics Company Profile
Orchard Therapeutics plc, integrated biopharmaceutical company, develops gene therapies for serious and life-threatening rare diseases. The company's gene therapy approach seeks to transform a patient's hematopoietic stem cells into a gene-modified drug product to treat the patient's disease through a single administration.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Orchard Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Orchard Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.